Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma.
Looking at options history for Verona Pharma VRNA we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 64% of the investors opened trades with bullish expectations and 28% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $319,653 and 7, calls, for a total amount of $262,865.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $45.0 to $60.0 for Verona Pharma during the past quarter.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Verona Pharma's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Verona Pharma's significant trades, within a strike price range of $45.0 to $60.0, over the past month.
Verona Pharma Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRNA | PUT | SWEEP | BEARISH | 02/21/25 | $3.7 | $3.7 | $3.7 | $55.00 | $75.1K | 0 | 1.0K |
| VRNA | PUT | SWEEP | BEARISH | 02/21/25 | $4.3 | $4.2 | $4.3 | $55.00 | $68.3K | 0 | 715 |
| VRNA | CALL | SWEEP | BULLISH | 01/17/25 | $5.4 | $5.1 | $5.4 | $45.00 | $56.9K | 2.3K | 80 |
| VRNA | PUT | SWEEP | BULLISH | 02/21/25 | $4.8 | $4.8 | $4.8 | $55.00 | $46.5K | 0 | 420 |
| VRNA | PUT | SWEEP | BULLISH | 03/21/25 | $6.1 | $5.2 | $5.1 | $55.00 | $41.8K | 0 | 82 |
About Verona Pharma
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Following our analysis of the options activities associated with Verona Pharma, we pivot to a closer look at the company's own performance.
Present Market Standing of Verona Pharma
- Currently trading with a volume of 1,114,755, the VRNA's price is up by 5.52%, now at $53.09.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 42 days.
Professional Analyst Ratings for Verona Pharma
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $66.33333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Truist Securities downgraded its action to Buy with a price target of $57. * Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Verona Pharma with a target price of $74. * An analyst from Roth MKM downgraded its action to Buy with a price target of $68.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Verona Pharma options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
